Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

The Cooper Companies, Inc. through its subsidiaries, develops, manufactures, and markets specialty healthcare products. The Company"s products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians.
Website: coopercos.com



Growth: Pretty weak revenue growth rate 9.3%, there is slowdown compared to average historical growth rates 14.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +26.5%. On average the margin is improving unsteadily. Gross margin is high, +65.4%. In the last quarter the company beat the estimated EPS, +1.7%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 2.0% higher than minimum and 80.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.4x by EV / Sales multiple , the company can be 39.8% overvalued

Insiders: For the last 3 months insiders sold company shares on $30.3 mln (-0.149% of cap.)

Key Financials (Download financials)

Ticker: COO
Share price, USD:  (+1.0%)90.64
year average price 306.12  


year start price 385.94 2023-05-07

max close price 397.36 2023-07-14

min close price 88.84 2024-04-26

current price 90.64 2024-05-05
Common stocks: 199 900 000

Dividend Yield:  0.0%
FCF Yield LTM: 1.0%
EV / LTM EBITDA: 21.6x
EV / EBITDA annualized: 26.0x
Last revenue growth (y/y):  9.3%
Last growth of EBITDA (y/y):  19.3%
Historical revenue growth:  14.4%
Historical growth of EBITDA:  18.6%
EV / Sales: 5.7x
Margin (EBITDA LTM / Revenue): 26.5%
Fundamental value created in LTM:
Market Cap ($m): 18 119
Net Debt ($m): 2 448
EV (Enterprise Value): 20 567
Price to Book: 2.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-24Zacks Investment Research

The Cooper Companies (COO) Upgraded to Buy: What Does It Mean for the Stock?

2024-04-17Zacks Investment Research

LH vs. COO: Which Stock Should Value Investors Buy Now?

2024-04-12Zacks Investment Research

Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now

2024-03-21Seeking Alpha

The Cooper Companies: Rating Upgrade As Near-Term Momentum Should Continue

2024-03-12Zacks Investment Research

LH or COO: Which Is the Better Value Stock Right Now?

2024-03-11Zacks Investment Research

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

2024-03-01Seeking Alpha

The Cooper Companies, Inc. (COO) Q1 20243 Earnings Call Transcript

2024-03-01Zacks Investment Research

Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised

2024-02-29Zacks Investment Research

The Cooper Companies (COO) Reports Q1 Earnings: What Key Metrics Have to Say

2024-02-29Zacks Investment Research

The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol COO COO COO COO COO COO
reportedCurrency USD USD USD USD USD USD
cik 711 404 711 404 711 404 711 404 711 404 711 404
fillingDate 2024-03-01 2023-12-08 2023-08-31 2023-06-02 2023-03-03 2022-12-09
acceptedDate 2024-03-01 16:17:31 2023-12-08 16:15:18 2023-08-31 16:17:02 2023-06-02 16:17:05 2023-03-03 16:16:44 2022-12-09 16:16:43
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4
revenue 932M 927M 930M 877M 859M 848M
costOfRevenue 358M 321M 320M 295M 300M 312M
grossProfit 574M 607M 610M 583M 559M 537M
grossProfitRatio 0.616 0.654 0.656 0.664 0.651 0.633
researchAndDevelopmentExpenses 40M 37M 37M 33M 32M 29M
generalAndAdministrativeExpenses 0 0 375M 408M 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 381M 388M 375M 408M 331M 358M
otherExpenses -2M -3M -6M 47M 47M 46M
operatingExpenses 420M 471M 458M 487M 409M 433M
costAndExpenses 779M 791M 779M 781M 709M 745M
interestIncome 0 0 0 0 0 0
interestExpense 44M 26M 27M 26M 26M 23M
depreciationAndAmortization 97M 47M 47M 42M 45M 38M
ebitda 250M 179M 192M 138M 195M 141M
ebitdaratio 0.268 0.193 0.207 0.158 0.227 0.166
operatingIncome 153M 136M 152M 96M 150M 104M
operatingIncomeRatio 0.164 0.146 0.163 0.110 0.174 0.122
totalOtherIncomeExpensesNet -33M -3M -6M -31M -27M -31M
incomeBeforeTax 120M 106M 119M 66M 122M 72M
incomeBeforeTaxRatio 0.129 0.115 0.128 0.075 0.142 0.085
incomeTaxExpense 39M 22M 34M 26M 38M 7M
netIncome 81M 85M 85M 40M 85M 66M
netIncomeRatio 0.087 0.091 0.092 0.045 0.099 0.077
eps 0.410 0.430 1.720 0.800 1.710 1.330
epsdiluted 0.410 0.420 1.710 0.800 1.700 1.320
weightedAverageShsOut 198M 198M 50M 49M 49M 49M
weightedAverageShsOutDil 200M 200M 50M 50M 50M 50M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol COO COO COO COO COO COO
reportedCurrency USD USD USD USD USD USD
cik 711 404 711 404 711 404 711 404 711 404 711 404
fillingDate 2024-03-01 2023-12-08 2023-08-31 2023-06-02 2023-03-03 2022-12-09
acceptedDate 2024-03-01 16:17:31 2023-12-08 16:15:18 2023-08-31 16:17:02 2023-06-02 16:17:05 2023-03-03 16:16:44 2022-12-09 16:16:43
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4
cashAndCashEquivalents 135M 121M 117M 112M 118M 138M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 135M 121M 117M 112M 118M 138M
netReceivables 651M 610M 630M 565M 582M 558M
inventory 748M 736M 724M 699M 659M 629M
otherCurrentAssets 260M 239M 240M 224M 218M 209M
totalCurrentAssets 1 794M 1 705M 1 711M 1 599M 1 578M 1 534M
propertyPlantEquipmentNet 1 682M 1 633M 1 535M 1 490M 1 464M 1 433M
goodwill 3 773M 3 625M 3 683M 3 660M 3 672M 3 610M
intangibleAssets 1 848M 1 710M 1 771M 1 815M 1 863M 1 885M
goodwillAndIntangibleAssets 5 621M 5 335M 5 454M 5 475M 5 536M 5 495M
longTermInvestments 0 0 0 0 0 0
taxAssets 2 318M 2 350M 2 369M 2 391M 2 415M 2 443M
otherNonCurrentAssets 617M 637M 628M 585M 569M 588M
totalNonCurrentAssets 10 239M 9 954M 9 986M 9 940M 9 984M 9 959M
otherAssets 0 0 0 0 0 0
totalAssets 12 033M 11 659M 11 697M 11 540M 11 561M 11 492M
accountPayables 202M 262M 227M 242M 224M 249M
shortTermDebt 46M 45M 80M 75M 68M 413M
taxPayables 0 0 0 0 0 0
deferredRevenue 122M 124M 123M 120M 106M 94M
otherCurrentLiabilities 594M 538M 565M 513M 517M 525M
totalCurrentLiabilities 965M 969M 994M 949M 916M 1 280M
longTermDebt 2 723M 2 524M 2 515M 2 566M 2 627M 2 351M
deferredRevenueNonCurrent 186M 184M 186M 183M 195M 198M
deferredTaxLiabilitiesNonCurrent 90M 102M 138M 139M 144M 150M
otherNonCurrentLiabilities 373M 329M 337M 325M 343M 2 282M
totalNonCurrentLiabilities 3 372M 3 139M 3 175M 3 212M 3 310M 3 037M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 3M 4M 20M 20M 20M 21M
totalLiabilities 4 337M 4 108M 4 169M 4 162M 4 225M 4 318M
preferredStock 0 0 200 000 0 0 0
commonStock 22M 5M 5M 5M 5M 5M
retainedEarnings 6 957M 6 876M 6 792M 6 708M 6 668M 6 585M
accumulatedOtherComprehensiveIncomeLoss -422M -454M -375M -424M -404M -467M
othertotalStockholdersEquity 1 138M 1 123M 1 106M 1 089M 1 066M 1 051M
totalStockholdersEquity 7 695M 7 551M 7 529M 7 378M 7 336M 7 175M
totalEquity 7 695M 7 551M 7 529M 7 378M 7 336M 7 175M
totalLiabilitiesAndStockholdersEquity 12 033M 11 659M 11 697M 11 540M 11 561M 11 493M
minorityInterest 200 000 200 000 200 000 200 000 200 000 200 000
totalLiabilitiesAndTotalEquity 12 033M 11 659M 11 697M 11 540M 11 561M 11 493M
totalInvestments 0 0 0 0 0 0
totalDebt 2 772M 2 569M 2 594M 2 640M 2 695M 2 763M
netDebt 2 637M 2 448M 2 477M 2 528M 2 577M 2 625M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol COO COO COO COO COO COO
reportedCurrency USD USD USD USD USD USD
cik 711 404 711 404 711 404 711 404 711 404 711 404
fillingDate 2024-03-01 2023-12-08 2023-08-31 2023-06-02 2023-03-03 2022-12-09
acceptedDate 2024-03-01 16:17:31 2023-12-08 16:15:18 2023-08-31 16:17:02 2023-06-02 16:17:05 2023-03-03 16:16:44 2022-12-09 16:16:43
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4
netIncome 81M 85M 85M 40M 85M 66M
depreciationAndAmortization 97M 93M 95M 91M 90M 89M
deferredIncomeTax 0 45M 1M 2M 0 -1M
stockBasedCompensation 0 0 16M 15M 0 0
changeInWorkingCapital -110M -30M -86M -75M -28M -165M
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 0
otherWorkingCapital -110M -30M -86M 0 0 0
otherNonCashItems 54M 27M 32M 52M 20M 143M
netCashProvidedByOperatingActivities 123M 174M 143M 124M 167M 131M
investmentsInPropertyPlantAndEquipment -118M -145M -91M -74M -83M -95M
acquisitionsNet -206M -16M -2M -8M -30M -5M
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites -206M 41M 0 0 0 0
netCashUsedForInvestingActivites -324M -161M -93M -82M -113M -100M
debtRepayment -202M -464M -505M -559M -426M -12M
commonStockIssued 2M 17M 2M 0 0 0
commonStockRepurchased 0 -17M 0 0 0 0
dividendsPaid 0 -2M 0 0 0 -2M
otherFinancingActivites 413M 459M 460M 512M 349M -121M
netCashUsedProvidedByFinancingActivities 212M -7M -43M -47M -78M -134M
effectOfForexChangesOnCash 4M -4M -1M -2M 4M -5M
netChangeInCash 14M 3M 5M -6M -20M -108M
cashAtEndOfPeriod 135M 121M 118M 112M 119M 139M
cashAtBeginningOfPeriod 121M 118M 112M 119M 139M 247M
operatingCashFlow 123M 174M 143M 124M 167M 131M
capitalExpenditure -118M -145M -91M -74M -83M -95M
freeCashFlow 5M 29M 52M 51M 84M 36M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q3
2023-12-07 ET (fiscal 2023 q4)
2023 q2
2023-08-30 ET (fiscal 2023 q3)
2023 q1
2023-06-01 ET (fiscal 2023 q2)
2022 q4
2023-03-02 ET (fiscal 2023 q1)
2022 q3
2022-12-08 ET (fiscal 2022 q4)
2022 q2
2022-08-31 ET (fiscal 2022 q3)
2022 q1
2022-06-02 ET (fiscal 2022 q2)
2021 q4
2022-03-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-29 21:15 ET
CooperCompanies Announces First Quarter 2024 Results
2024-02-15 21:15 ET
CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)
2024-01-25 21:15 ET
CooperCompanies Announces Release Date for First Quarter 2024
2023-12-21 21:15 ET
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
2023-12-19 21:15 ET
CooperCompanies Sets Annual Meeting And Stockholder Record Dates
2023-12-07 21:15 ET
CooperCompanies Announces Fourth Quarter and Full Year 2023 Results
2023-11-30 21:15 ET
CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors
2023-11-02 20:15 ET
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2023
2023-09-12 20:15 ET
CooperCompanies Announces Transfer of Stock Exchange Listing to Nasdaq
2023-09-11 20:15 ET
CooperCompanies to Present at the Baird Healthcare Conference
2023-09-08 19:44 ET
Cord Blood Registry® Announces Thought Leadership Role at Cord Blood Connect
2023-08-30 20:15 ET
CooperCompanies Announces Third Quarter 2023 Results
2023-08-02 20:14 ET
CooperCompanies to Present at the Wells Fargo Healthcare Conference
2023-07-27 20:33 ET
Chrissy Teigen Selects Cord Blood Registry® to Preserve Fourth Child's Newborn Stem Cells
2023-07-26 20:15 ET
CooperCompanies Announces Release Date for Third Quarter 2023
2023-07-12 20:15 ET
CooperCompanies Declares Cash Dividend
2023-06-01 20:15 ET
CooperCompanies Announces Second Quarter 2023 Results
2023-05-23 20:15 ET
CooperCompanies to Present at the Jefferies Healthcare Conference
2023-05-16 13:45 ET
CooperSurgical® and Ostro Named Best Patient Education Solution in the 7th Annual MedTech Breakthrough Awards
2023-05-09 20:15 ET
CooperCompanies Publishes 2022 Environmental, Social, and Governance Report, Shares Progress on Creating Value for Stakeholders
2023-04-27 20:15 ET
CooperCompanies Announces Release Date for Second Quarter 2023
2023-04-25 12:45 ET
CooperSurgical® Partners with The Noble Paperie to Support Families Struggling with Infertility
2023-03-02 21:15 ET
CooperCompanies Announces First Quarter 2023 Results
2023-03-01 14:00 ET
CooperVision's Latest Innovation, MyDay Energys® Contact Lenses, Make U.S. Debut
2023-02-28 21:15 ET
CooperCompanies to Present at KeyBanc Life Sciences & MedTech Investor Forum
2023-02-15 21:15 ET
CooperCompanies to Present at Oppenheimer’s 33rd Annual Healthcare Conference
2023-02-08 14:02 ET
Chrissy Teigen Partners with Cord Blood Registry®
2023-02-02 21:15 ET
CooperCompanies Announces Release Date for First Quarter 2023
2023-01-19 21:32 ET
The National Institute for Health and Care Excellence Recommends Fetal Pillow® As Standard Arrangements
2023-01-05 21:32 ET
CooperSurgical® Announces More than 11,000 Families Have Enrolled in Newborn Possibilities Program®
2022-12-19 21:15 ET
CooperCompanies Sets Annual Meeting and Stockholder Record Dates
2022-12-14 21:15 ET
CooperCompanies Declares Cash Dividend
2022-12-14 19:41 ET
CooperSurgical® partners with Ostro to educate consumers about Paragard® (intrauterine copper contraceptive)
2022-12-08 21:15 ET
CooperCompanies Announces Fourth Quarter and Full Year 2022 Results
2022-11-03 20:15 ET
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2022
2022-11-03 12:05 ET
CooperVision Adds SynergEyes to Expand Specialty Contact Lens Adoption in North America
2022-10-03 20:15 ET
CooperCompanies Appoints Cynthia Lucchese to Board of Directors
2022-09-01 10:00 ET
CooperVision to Share New Analysis of MiSight® 1 Day Treatment Effects During International Myopia Conference Event
2022-08-31 20:15 ET
CooperCompanies Announces Third Quarter 2022 Results
2022-08-18 20:15 ET
CooperCompanies to Participate in the Wells Fargo Healthcare Conference
2022-08-09 20:15 ET
CooperCompanies Appoints Nicholas Khadder as General Counsel and Corporate Secretary
2022-07-27 20:15 ET
CooperCompanies Announces Release Date for Third Quarter 2022
2022-07-13 20:15 ET
CooperCompanies Declares Cash Dividend
2022-06-02 20:15 ET
CooperCompanies Announces Second Quarter 2022 Results
2022-05-23 16:00 ET
CooperVision Appoints Alex Wilkes as President, Americas
2022-05-12 20:15 ET
CooperCompanies to Participate in the Jefferies Healthcare Conference
2022-05-11 20:15 ET
CooperCompanies Releases 2021 Environmental, Social, and Governance Highlights Report, Signs on to United Nations Global Compact
2022-04-21 20:15 ET
CooperCompanies and Cook® Medical Receive Second Requests from FTC under HSR Act
2022-03-17 20:20 ET
SightGlass Vision Joint Venture Begins Operation
2022-03-10 13:00 ET
Peer Review Affirms MiSight® 1 day Sustains Slowing of Eye Growth Over Six Years for Myopia Control
2022-03-03 21:15 ET
CooperCompanies Announces First Quarter 2022 Results
2022-02-17 21:15 ET
CooperCompanies to Present at Oppenheimer’s 32nd Annual Healthcare Conference
2022-02-07 22:32 ET
Cook Medical Reproductive Health Business to be Acquired by CooperCompanies
2022-02-07 21:15 ET
CooperCompanies to Acquire Cook® Medical’s Reproductive Health Business
2022-01-27 21:15 ET
CooperCompanies Announces Release Date for First Quarter 2022
2022-01-06 21:15 ET
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
2021-12-17 21:15 ET
CooperCompanies Completes Acquisition of Generate Life Sciences®
2021-12-15 21:15 ET
CooperCompanies Sets Annual Meeting and Stockholder Record Dates
2021-12-08 21:15 ET
CooperCompanies Declares Cash Dividend
2021-12-02 21:15 ET
CooperCompanies Announces Fourth Quarter and Full Year 2021 Results
2021-11-18 14:00 ET
CooperCompanies Announces Executive Management Changes
2021-11-10 22:45 ET
Generate Life Sciences to be acquired by CooperCompanies
2021-11-10 21:20 ET
GI Partners Announces Agreement to Sell Generate Life Sciences to CooperCompanies
2021-11-10 21:15 ET
CooperCompanies to Acquire Generate Life Sciences® for $1.6 Billion
2021-11-02 20:15 ET
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2021
2021-10-12 12:00 ET
CooperVision Launches New Myopia Education Campaign for U.S. Parents
2021-09-10 11:05 ET
CooperCompanies and Divisions Named One of Fortune Magazine’s Best Large Workplaces
2021-09-02 20:15 ET
CooperCompanies Announces Third Quarter 2021 Results
2021-08-31 12:30 ET
CooperVision Proudly Names Mitsou as Québec Spokesperson to Raise Awareness Around Myopia in Children
2021-08-12 20:15 ET
CooperCompanies to Participate in the Virtual Wells Fargo Healthcare Conference
2021-08-12 13:00 ET
CooperCompanies Announces MiSight® Approval in China
2021-07-29 20:15 ET
CooperCompanies Announces Release Date for Third Quarter 2021
2021-07-14 20:15 ET
CooperCompanies Declares Cash Dividend
2021-07-14 13:15 ET
clariti® 1 day Becomes First Net Plastic Neutral Contact Lens in the U.S.
2021-06-28 13:36 ET
No Rest for the Weary Eyes: A Pandemic of Increased Near-Vision Use for Canadian Children(1) – CooperVision Survey
2021-06-15 20:15 ET
CooperCompanies Releases 2020 Environmental, Social, and Governance Report
2021-06-03 20:15 ET
CooperCompanies Announces Second Quarter 2021 Results
2021-05-25 12:00 ET
CooperVision DreamLite® Ortho-K Lenses Gain European Approval for Slowing Progression of Myopia
2021-05-12 20:15 ET
CooperCompanies Elects Maria Rivas, MD to Board of Directors
2021-05-03 20:15 ET
CooperCompanies Acquires obp Medical
2021-04-29 20:15 ET
CooperCompanies Announces Release Date for Second Quarter 2021
2021-03-24 20:15 ET
CooperCompanies Announces New Board Appointments
2021-03-05 14:00 ET
TMRW Appoints Brian E. Miller, Ph.D., as SVP of Sales
2021-03-04 21:15 ET
CooperCompanies Announces First Quarter 2021 Results
2021-03-02 21:15 ET
CooperCompanies to Participate in the KeyBanc Life Sciences MedTech Investor Forum
2021-03-01 21:15 ET
CooperCompanies Acquires Safe Obstetric Systems
2021-02-18 21:15 ET
CooperCompanies to Participate in the Oppenheimer Annual Healthcare Conference
2021-02-04 21:15 ET
CooperCompanies Announces Release Date for First Quarter 2021
2021-02-03 21:20 ET
EssilorLuxottica and CooperCompanies Announce Joint Venture for Acquisition of SightGlass Vision
2021-02-02 15:00 ET
CooperSurgical® Acquires AEGEA Medical
2021-01-26 21:15 ET
CooperCompanies Awarded Great Place to Work® Certification
2021-01-07 21:15 ET
CooperCompanies Declares Cash Dividend
2020-12-21 21:15 ET
CooperCompanies to Present at J.P. Morgan Healthcare Conference
2020-12-17 21:15 ET
CooperCompanies Sets Annual Meeting and Stockholder Record Dates
2020-12-10 21:15 ET
A. Thomas Bender and Allan E. Rubenstein, M.D. to Retire from CooperCompanies Board
2020-12-03 21:15 ET
CooperCompanies Announces Fourth Quarter and Full Year 2020 Results
2020-11-12 21:15 ET
CooperCompanies Elects Teresa S. Madden to Board of Directors
2020-11-10 13:00 ET
Following U.S. Success, CooperVision's Brilliant Futures™ Myopia Management Program Expands Globally
2020-11-03 21:15 ET
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2020
2020-10-19 18:11 ET
CooperSurgical and NYU Langone Fertility Center Announce Study Data Showing Significant Increase in Ongoing Pregnancy and Live Birth Rates with Genetic Test Using Artificial Intelligence (PGTai 2.0 platform) for Patients Undergoing IVF
2020-10-09 12:00 ET
CooperVision Presents Six-Year Data from MiSight® 1 Day Study; 23% of Eyes Showed No Additional Myopia Progression After Fitting
2020-09-10 11:15 ET
CooperCompanies and Divisions Named One of Fortune’s Best Large Workplaces in Manufacturing and Production
2020-09-03 20:15 ET
CooperCompanies Announces Third Quarter 2020 Results
2020-08-31 20:15 ET
CooperCompanies to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2020-08-26 16:30 ET
CooperVision Announces Sarah Michelle Gellar as Spokesperson to Increase Awareness of Myopia Management and the Brilliant Futures™ Program with MiSight® 1 day Contact Lens
2020-08-19 20:15 ET
CooperCompanies to Participate in the Morgan Stanley Virtual Global Healthcare Conference
2020-08-13 20:15 ET
CooperCompanies to Participate in the Wells Fargo Virtual Healthcare Conference
2020-08-06 20:15 ET
CooperCompanies Announces Release Date for Third Quarter 2020
2020-07-09 20:15 ET
CooperCompanies Declares Cash Dividend
2020-07-06 20:15 ET
CooperCompanies Appoints Holly Sheffield as President, CooperSurgical and Announces Robert Auerbach, M.D. to Retire
2020-03-05 21:15 ET
CooperCompanies Announces First Quarter 2020 Results
2020-02-18 21:15 ET
CooperCompanies to Participate in the Oppenheimer Annual Healthcare Conference
2020-02-12 21:15 ET
CooperCompanies Joins Major Corporations in Signing CEO Action for Diversity & Inclusion™ Pledge
2020-02-11 21:15 ET
CooperCompanies to Participate in the Barclays Global Healthcare Conference
2020-02-07 21:15 ET
CooperCompanies Appoints Mark Drury as New Vice President, General Counsel and Corporate Secretary and Announces Randal L. Golden to Retire
2020-02-04 21:15 ET
CooperCompanies Announces Release Date for First Quarter 2020
2020-01-07 21:15 ET
CooperCompanies Declares Cash Dividend
2019-12-19 21:15 ET
CooperCompanies Sets Annual Meeting and Stockholder Record Dates
2019-12-09 21:15 ET
CooperCompanies to Present at J.P. Morgan Healthcare Conference
2019-12-05 21:15 ET
CooperCompanies Announces Fourth Quarter and Full Year 2019 Results
2019-11-18 13:30 ET
Breakthrough CooperVision MiSight® 1 Day Contact Lens for Childhood Myopia  Coming to the United States in 2020
2019-11-18 13:15 ET
CooperCompanies Announces CooperVision Has Received FDA Approval of MiSight® for the Treatment of Myopia in Children
2019-11-07 21:15 ET
CooperCompanies Announces Global Support for Optometry Giving Sight and March of Dimes, Introduces All-Employee Matching Gifts Program
2019-11-05 13:30 ET
New Survey Shows Parents Know More About Lice Than They Do About Myopia
2019-03-05 21:15 ET
The Cooper Companies Announces First Quarter 2019 Results
2019-02-12 21:15 ET
The Cooper Companies to Participate in the Barclays Global Healthcare Conference
2019-01-31 21:15 ET
The Cooper Companies Announces Release Date for First Quarter 2019

SEC forms

Show financial reports only

SEC form 10
2024-03-01 16:17 ET
Cooper reported for 2023 q4
SEC form 10
2024-03-01 00:00 ET
Cooper reported for 2023 q4
SEC form 8
2024-02-29 16:20 ET
Cooper published news for 2023 q4
SEC form 8
2024-02-29 16:20 ET
Cooper reported for 2023 q4
SEC form 10
2023-12-08 16:15 ET
Cooper published news for 2023 q3
SEC form 10
2023-12-08 00:00 ET
Cooper published news for 2023 q3
SEC form 8
2023-12-07 16:20 ET
Cooper reported for 2023 q3
SEC form 10
2023-08-31 00:00 ET
Cooper reported for 2023 q2
SEC form 8
2023-08-30 00:00 ET
Cooper published news for 2023 q2
SEC form 10
2023-06-02 16:17 ET
Cooper published news for 2023 q1
SEC form 10
2023-06-02 00:00 ET
Cooper published news for 2023 q1
SEC form 6
2023-06-01 16:19 ET
Cooper reported for 2023 q1
SEC form 8
2023-06-01 00:00 ET
Cooper published news for 2023 q1
SEC form 6
2023-03-16 17:18 ET
Cooper published news for 2022 q4
SEC form 10
2023-03-03 16:16 ET
Cooper published news for 2022 q4
SEC form 10
2023-03-03 00:00 ET
Cooper reported for 2022 q4
SEC form 6
2023-03-02 16:20 ET
Cooper published news for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Cooper reported for 2022 q4
SEC form 6
2023-01-30 16:09 ET
Cooper published news for 2022 q4
SEC form 6
2022-12-19 17:23 ET
Cooper published news for 2022 q3
SEC form 10
2022-12-09 16:16 ET
Cooper published news for 2022 q3
SEC form 10
2022-12-09 00:00 ET
Cooper published news for 2022 q3
SEC form 6
2022-12-08 16:20 ET
Cooper published news for 2022 q3
SEC form 8
2022-12-08 00:00 ET
Cooper reported for 2022 q3
SEC form 6
2022-10-04 16:08 ET
Cooper published news for 2022 q3
SEC form 10
2022-09-01 16:14 ET
Cooper published news for 2022 q2
SEC form 10
2022-09-01 00:00 ET
Cooper reported for 2022 q2
SEC form 6
2022-08-31 16:23 ET
Cooper published news for 2022 q2
SEC form 8
2022-08-31 00:00 ET
Cooper reported for 2022 q2
SEC form 10
2022-06-03 16:18 ET
Cooper published news for 2022 q1
SEC form 10
2022-06-03 00:00 ET
Cooper reported for 2022 q1
SEC form 6
2022-06-02 16:22 ET
Cooper published news for 2022 q1
SEC form 8
2022-06-02 00:00 ET
Cooper reported for 2022 q1
SEC form 6
2022-03-18 16:02 ET
Cooper published news for 2021 q4
SEC form 10
2022-03-04 16:16 ET
Cooper published news for 2021 q4
SEC form 10
2022-03-04 00:00 ET
Cooper published news for 2021 q4
SEC form 6
2022-03-03 16:19 ET
Cooper published news for 2021 q4
SEC form 8
2022-03-03 00:00 ET
Cooper published news for 2021 q4
SEC form 6
2022-02-07 17:20 ET
Cooper published news for 2021 q4
SEC form 6
2022-01-28 16:54 ET
Cooper published news for 2021 q4
SEC form 6
2021-12-17 16:25 ET
Cooper published news for 2021 q3
SEC form 10
2021-12-10 16:17 ET
Cooper published news for 2021 q3
SEC form 6
2021-12-10 16:03 ET
Cooper published news for 2021 q3
SEC form 10
2021-12-10 00:00 ET
Cooper published news for 2021 q3
SEC form 6
2021-12-02 16:17 ET
Cooper published news for 2021 q3
SEC form 8
2021-12-02 00:00 ET
Cooper published news for 2021 q3
SEC form 6
2021-11-10 17:18 ET
Cooper published news for 2021 q3
SEC form 6
2021-11-05 16:32 ET
Cooper published news for 2021 q3
SEC form 10
2021-09-03 16:17 ET
Cooper published news for 2021 q2
SEC form 10
2021-09-03 00:00 ET
Cooper published news for 2021 q2
SEC form 6
2021-09-02 16:22 ET
Cooper published news for 2021 q2
SEC form 8
2021-09-02 00:00 ET
Cooper published news for 2021 q2
SEC form 10
2021-06-04 16:02 ET
Cooper published news for 2021 q1
SEC form 10
2021-06-04 00:00 ET
Cooper published news for 2021 q1
SEC form 6
2021-06-03 16:18 ET
Cooper published news for 2021 q1
SEC form 8
2021-06-03 00:00 ET
Cooper published news for 2021 q1
SEC form 6
2021-05-12 16:46 ET
Cooper published news for 2021 q1
SEC form 6
2021-03-23 16:03 ET
Cooper published news for 2020 q4
SEC form 10
2021-03-05 16:02 ET
Cooper published news for 2020 q4
SEC form 6
2021-03-04 16:18 ET
Cooper published news for 2020 q4
SEC form 6
2021-02-02 16:00 ET
Cooper published news for 2020 q4
SEC form 6
2021-01-29 16:06 ET
Cooper published news for 2020 q4
SEC form 10
2020-12-11 16:37 ET
Cooper published news for 2020 q3
SEC form 6
2020-12-10 16:34 ET
Cooper published news for 2020 q3
SEC form 6
2020-12-03 16:23 ET
Cooper published news for 2020 q3
SEC form 6
2020-11-12 16:35 ET
Cooper published news for 2020 q3